Skip to content

Jhanelle E. Gray

Institut Gustave Roussy

3 papers in the Anchorcite directory, published between 2017 and 2018, cited 17,109 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Rina Hui · 2 papers
  • Takayasu Kurata · 2 papers
  • Ki Hyeong Lee · 2 papers
  • Byoung Chul Cho · 2 papers
  • David Planchard · 2 papers
  • Leena Gandhi · 1 paper
  • Delvys Rodríguez‐Abreu · 1 paper
  • Shirish M. Gadgeel · 1 paper

Papers

  1. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations

    BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…

  2. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations

    BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…

  3. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 4,715 citations

    BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in…

Metadata from OpenAlex (CC0).